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Summary
Background HIV-1 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been 
identiﬁ ed in sub-Saharan Africa in patients with virological failure of ﬁ rst-line combination antiretroviral therapy (ART) 
containing the modern nucleoside reverse transcriptase inhibitor tenofovir. We aimed to investigate the prevalence and 
correlates of thymidine analogue mutations (TAM) in patients with virological failure of ﬁ rst-line tenofovir-containing ART.
Methods We retrospectively analysed patients from 20 studies within the TenoRes collaboration who had locally 
deﬁ ned viral failure on ﬁ rst-line therapy with tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a 
non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa. Baseline 
visits in these studies occurred between 2005 and 2013. To assess between-study and within-study associations, we 
used meta-regression and meta-analyses to compare patients with and without TAMs for the presence of resistance to 
tenofovir, cytosine analogue, or NNRTIs.
Findings Of 712 individuals with failure of ﬁ rst-line tenofovir-containing regimens, 115 (16%) had at least one TAM. In 
crude comparisons, patients with TAMs had lower CD4 counts at treatment initiation than did patients without TAMs 
(60·5 cells per μL [IQR 21·0–128·0] in patients with TAMS vs 95·0 cells per μL [37·0–177·0] in patients without 
TAMs; p=0·007) and were more likely to have tenofovir resistance (93 [81%] of 115 patients with TAMs vs 352 [59%] of 
597 patients without TAMs; p<0·0001), NNRTI resistance (107 [93%] vs 462 [77%]; p<0·0001), and cytosine analogue 
resistance (100 [87%] vs 378 [63%]; p=0·0002). We detected associations between TAMs and drug resistance mutations 
both between and within studies; the correlation between the study-level proportion of patients with tenofovir 
resistance and TAMs was 0·64 (p<0·0001), and the odds ratio for tenofovir resistance comparing patients with and 
without TAMs was 1·29 (1·13–1·47; p<0·0001)
Interpretation TAMs are common in patients who have failure of ﬁ rst-line tenofovir-containing regimens in 
sub-Saharan Africa, and are associated with multidrug resistant HIV-1. Eﬀ ective viral load monitoring and point-of-care 
resistance tests could help to mitigate the emergence and spread of such strains.
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Introduction
Combination antiretroviral therapy (cART) can lead to 
declining mortality and HIV incidence in high 
prevalence settings.1,2 Virological failure occurs after 
12 months in 15–35% of patients treated with thymidine 
analogue-containing ﬁ rst-line regimens (eg, zidovudine 
or stavudine plus lamivudine plus nevirapine or 
efavirenz), with most cases of resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTIs) 
and lamivudine occurring in regions without access to 
routine viral load monitoring.3,4 HIV-1 drug resistance 
could be responsible for nearly 425 000 AIDS-related 
deaths and 300 000 new infections over the next 
5 years.5
WHO has recommended ﬁ rst-line tenofovir disoproxil 
fumarate (tenofovir) instead of thymidine analogues since 
2012.6 Of the 17 million people accessing ﬁ rst-line ART in 
2016,7 roughly 3·5 million were treated with a thymidine 
analogue.8 During the process of pro gram matic tenofovir 
sub stitution in ART-treated individuals (including 
children), conﬁ rmation of viral suppression before 
the regimen change (within 30 days) is rarely done in 
sub-Saharan Africa because of poor access to viral load 
testing. Given the potential substantial prevalence of 
unrecognised virological failure and drug resistance in 
this setting,4,9–11 programmatic single-drug substitutions 
risk more rapid acquisition of high-level drug resistance 
not only to NNRTIs and cytosine analogues, but also to 
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tenofovir.12 Importantly, NNRTI resistance and thymidine 
analogue resistance mutations (TAMs) can be transmitted 
to uninfected individuals who are subsequently at 
increased risk of ART failure themselves.13
A further complication to the introduction of tenofovir in 
sub-Saharan Africa is shown by data suggesting that 
individuals presenting as treatment naive often do not 
disclose previous ART exposure, which is most likely with 
thymidine analogue-based ART.14 Accordingly, we have 
previously reported unexplained TAMs in patients after 
viral failure of tenofovir-containing ﬁ rst-line regimens.15 In 
this Article, we characterise the prevalence, determinants, 
and implications of TAMs in patients after virological 
failure of tenofovir-containing ﬁ rst-line regimens in 
sub-Saharan Africa.
Methods
Study population and design
We identiﬁ ed patients from within the TenoRes col-
laboration, a multicountry retrospective study examining 
correlates of genotypic drug resistance following failure 
of tenofovir-containing combination ART. Data in this 
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Research in context
Evidence before this study
We did a systematic review using PubMed and Embase, 
searching from Jan 1, 2000, up to Aug 15, 2016, without 
language limitations. Manuscripts of interest were also 
identiﬁ ed from the reference lists of selected papers, clinical 
trials registries, and abstracts from the Conference on 
Retroviruses and Opportunistic Infections (CROI) and 
International AIDS Society (IAS). We used the search terms 
“HIV” AND “Tenofovir” AND “thymidine analogue” OR 
“stavudine” OR “zidovudine” OR “AZT” OR “d4T”. We found no 
studies reporting the implications of previous thymidine 
analogue use on outcomes following tenofovir-based 
antiretroviral therapy (ART). One study investigated the 
implications of transition from thymidine analogue to 
tenofovir by use of a cross sectional survey in Myanmar before 
the introduction of tenofovir. The investigators tested viral 
loads in more than 4000 patients after 12 months of thymidine 
analogue-based ART to avoid substitutions in viraemic 
patients. They noted that a substantial proportion of patients 
were having treatment failure (13% had viral loads >250 copies 
per mL), in whom direct tenofovir substitution for the 
thymidine analogue would not be appropriate.
Added value of this study
Our results show that tenofovir-based ﬁ rst-line regimens are 
failing in a substantial proportion of patients who have 
evidence of previous exposure and drug resistance to older 
nucleoside (thymidine) analogues such as zidovudine and 
stavudine in sub-Saharan Africa. These individuals are likely to 
have developed drug resistance to the non-nucleoside reverse 
transcriptase inhibitor as well as the cytosine analogue, and 
therefore have high-level resistance to at least two of the 
three drugs present in tenofovir-based ﬁ rst line ART. Our data 
show that these individuals with thymidine analogue 
mutations have lower CD4 counts and therefore are at 
greater risk of clinical complications than are those without 
previous ART exposure.
Implications of all the available evidence
Cheap and eﬀ ective viral load monitoring, resistance testing, or 
both could prevent the transition of patients with virological 
failure onto tenofovir-based ﬁ rst-line ART and also identify 
individuals with pre-existing drug resistance to ﬁ rst line agents 
arising from undisclosed prior ART. These individuals could then 
be treated with second-line regimens. 
Number of 
patients
Age at tenofovir 
initiation (years)
Women Nevirapine Emtricitabine Baseline CD4 count 
(cells per μL)
Baseline viral load 
(log10 copies per mL)
Year of tenofovir 
initiation
Length of time on 
tenofovir-based ART 
(months)
Eastern Africa
No TAM 133 36·0 (30·0–44·0) 77 (58%) 79 (59%) 44 (33%) 102·5 (40·5–208·5) 5·6 (5·3–5·8) 2011 (2010–2012) 14·2 (12·2–27·8)
TAM 26 33·5 (27·0–41·0) 17 (65%) 20 (77%) 7 (27%) 68·0 (16·5–209·0) 5·4 (5·1–5·8) 2011 (2011–2012) 13·3 (11·8–27·2)
Southern Africa
No TAM 383 34·5 (28·0–41·0) 225 (59%) 96 (25%) 72 (19%) 98·0 (39·0–167·0) 4·7 (3·4–5·4) 2011 (2008–2011) 19·0 (12·0–28·2)
TAM 78 34·0 (28·4–37·0) 48 (62%) 13 (17%) 7 (9%) 72·0 (20·0–107·0) 4·4 (2·9–5·3) 2010 (2010–2011) 21·0 (14·1–27·3)
West and central Africa
No TAM 81 36·1 (31·0–40·0) 42 (52%) 53 (65%) 65 (80%) 86·5 (30·0–180·0) 5·2 (4·9–5·6) 2006 (2006–2009) 14·2 (10·9–18·0)
TAM 11 36·3 (30·0–42·0) 4 (36%) 9 (82%) 9 (82%) 58·0 (27·0–143·0) 4·8 (3·7–5·5) 2006 (2006–2006) 12·4 (11·6–18·0)
Overall
No TAM 597 35·0 (29·0–41·0) 344 (58%) 228 (38%) 181 (30%) 95·0 (37·0–177·0) 5·2 (4·5–5·6) 2011 (2008–2011) 17·4 (12·0–27·0)
TAM 115 34·0 (28·0–38·1) 69 (60%) 42 (37%) 23 (20%) 60·5 (21·0–128·0) 5·1 (4·1–5·6) 2011 (2010–2012) 19·0 (12·9–27·0)
Data are median (IQR) or n (%) unless speciﬁ ed otherwise. Tenfovir=tenofovir disoproxil fumarate. ART=antiretroviral therapy.
Table 1: Baseline characteristics of patients by region and thymidine analogue mutation status 
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report cover seven countries with baseline measurements 
taken between 2005 and 2013. The original TenoRes 
collaboration spans 36 counties with baseline 
measurements between 1998 and 2015. Our methods 
have been described previously.15 Brieﬂ y, we collected data 
from cohorts with documented virological failure after 
ﬁ rst-line ART consisting only of tenofovir plus either 
lamivudine or emtricitabine plus either efavirenz or 
nevirapine, with no previously known exposure to 
additional nucleoside reverse transcriptase inhibitors 
such as zidovudine or stavudine (appendix). Virological 
failure was deﬁ ned as a viral load greater than 1000 copies 
per mL, except for two studies in which the deﬁ nition was 
viral load greater than 2000 copies per mL (appendix). 
Patients needed to have had a successful resistance test 
result associated with virological failure of combination 
ART and been on tenofovir-based ART for a minimum of 
4 months before virological failure. We collected 
information on baseline characteristics (age, sex, pre-
tenofovir CD4 count, pre-tenofovir viral load, and previous 
exposure to single-dose nevirapine for prevention of 
vertical trans mission), and HIV genotype following 
virological failure (eg, number and type of TAMs; 
presence of cytosine analogue, tenofovir, or NNRTI 
[ie, nevirapine and efavirenz] resistance). In our previous 
report,15 we excluded patients with TAMs because of 
concerns that they might represent pre-treated rather 
than ﬁ rst-line patients, although identical information 
was collected on patients irrespective of the presence or 
absence of TAMs at the resistance test.
We deﬁ ned tenofovir resistance as the presence of 
Lys65Arg/Asn or Lys70Glu/Gly/Gln mutations in 
reverse transcriptase. Although the presence of three or 
more TAMs inclusive of either the Met41Leu or 
Leu210Trp mutation has also been shown to compromise 
tenofovir clinically,12 no individuals in this study had 
such a proﬁ le. TAMs were deﬁ ned as Met41Leu, 
Asp67Asn, Lys70Arg, Leu210Trp, Thr215Phe/Tyr, or 
Lys219Gln/Glu. Our deﬁ nition of TAMs also included 
the revertant mutations Thr215Ser/Cys/Asp/Glu/Ile/
Val, although only two patients presented with such a 
mutation without the presence of at least one other 
TAM. TAM revertants are indicative of previous TAM 
Thr215Phe or Thr215Tyr mutations in the individual, 
and have been associated with increased risk of 
treatment failure if a thymidine analogue drug is used.16 
We restricted our analysis to study sites from 
sub-Saharan Africa because we speciﬁ cally wanted to 
investigate the large-scale programmatic shifts in 
tenofovir use that are currently occurring in this region 
in the absence of intensive viral load monitoring and 
baseline resistance testing. Studies were included if they 
had resistance data on ten or more patients, although in 
sensitivity analyses that included all available data, the 
conclusions were not altered (appendix).
We interpreted drug resistance mutations using the 
Stanford HIV Drug Resistance Algorithm version 7.0.
Statistical analysis
In cohorts spanning multiple countries, each country 
within the cohort was treated as a separate study for 
the purposes of our meta-analyses, to ensure that 
within-study associations were not confounded by 
between-country diﬀ erences. To compare baseline 
characteristics according to TAM resistance, we used 
Mann-Whitney U tests or χ² tests. We did three main 
analyses. First, we calculated prevalence estimates 
within each study separately and used Clopper-Pearson 
exact 95% CIs. Second, we graphically compared the 
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Figure 1: Estimated prevalence of TAMs and types of TAMs
(A) Estimated prevalence of TAMs by study site. Black lines show 95% CIs for estimated prevalence. (B) Number 
and type of TAMs identiﬁ ed across study sites. TAM=thymidine analogue mutation. *Prevalence estimate of 0% 
where the 95% CI uses the population size and the fact that no TAMs have occurred to put an upper limit on the 
estimated prevalence.
See Online for appendix
For the Stanford HIV Drug 
Resistance Algorithm see 
https://hivdb.stanford.edu/
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study-level prevalence of TAMs and other drug-resistance 
mutations and used Spearman’s rank correlation 
coeﬃ  cients to assess the strength of association between 
the two. Third, we calculated odds ratios for drug-
resistance mutations in patients with and without TAMs. 
We pooled estimates across studies using ﬁ xed-eﬀ ects 
meta-analyses with Mantel-Haenszel weighting. We 
chose this strategy because there was no evidence of any 
between-study heterogeneity, and Mantel-Haenszel 
weighting works well in scenarios with zero-cell counts. 
All analyses were done with STATA version 11.2.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RKG and JG had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We assessed 34 studies and excluded 14 because they 
contained fewer than ten patients (56 patients excluded). 
We identiﬁ ed 712 patients who had viral failure with 
WHO-recommended, tenofovir-based ﬁ rst-line regimens 
in 20 studies across sub-Saharan Africa (table 1; appendix). 
Most (461 [65%]) patients were from southern Africa, with 
159 (22%) patients from eastern Africa and 92 (13%) from 
west and central Africa. 481 (68%) of 712 infections were 
with HIV-1 subtype C (appendix). Median age at baseline 
was 35·0 years (IQR 28·8–40·7) and 413 (58%) patients 
were women. The median year of initiation was 2011, and 
patients were followed up for a median of 18 months 
(12–27). Where available, the overall median baseline CD4 
count was 92 cells per μL (34–169) and median viral load 
was log10 5·23 copies HIV-1 RNA (4·5–5·6) per mL. 
Patient characteristics were broadly similar between 
patients with and without TAMs, with the exception of 
baseline CD4 count, which was roughly 30 cells per μL 
lower in patients with TAMs in all regions (p=0·007). We 
noted that usage of emtricitabine was 10% lower in 
patients with TAM compared to those without. 33 (16%) 
of 209 women with available data on single-dose 
nevirapine had known previous exposure to single-dose 
nevirapine. Prevalence of NNRTI resistance was 88% (29 
of 33 patients) in patients with single-dose nevirapine 
exposure and 82% (378 of 462 patients overall or 142 [81%] 
of 176 women) in those without single-dose nevirapine 
exposure (p=0·38). For many patients, it was not known 
whether or not they had received single-dose nevirapine, 
including men, for whom single dose nevirapine use was 
always answered as no.
TAMs were detected in 115 (16%) of 712 patients 
(ﬁ gure 1A). The prevalence of TAMs was similar in 
eastern Africa (26 [16%] of 158), southern Africa 
(78 [17%] of 461 patients), and west and central Africa 
(11 [12%] of 92 patients). TAMs were less common in 
patients with HIV-1 subtype D than in patients with 
other subtypes (appendix). Despite individual studies 
tending to have only a small number of patients, all but 
four of the 20 included studies reported a prevalence of 
TAMs between 5% and 25% (ﬁ gure 1A). Asp67Asn was 
the most common TAM and was present in 50 (7%) of 
712 patients; it was more common in southern (41 [9%] 
of 461 patients) and eastern Africa (eight [5%] of 
159 patients) than in west and central Africa (one [1%] 
of 91 patients; p=0·015). The next most common TAMs 
were Lys219Glu (46 [6%] of 712 patients) and Met41Leu 
(20 [3%] patients; ﬁ gure 1B). 20 (3%) patients had two 
or more TAMs and seven (1%) patients had three or 
more TAMs.
In crude comparisons across the entire study population, 
patients with TAMs were more likely to have tenofovir 
resistance (p<0·0001), as well as resistance to cytosine 
analogues (100 [87%] patients with TAMs vs 378 [63%] of 
patients without TAMs; p=0·0002) and nevirapine or 
efavirenz (107 [93%] of 115 patients with TAMs vs 462 [77%] 
of 597 without TAMs; p<0·0001), with consistent ﬁ ndings 
across all regions (ﬁ gure 2). Of the 115 patients with 
TAMs, 93 (81%) had Lys65Arg/Asn or Lys70Glu/Gly/Gln, 
whereas in the remaining 597 patients without TAMs, 
352 (59%) patients had these tenofovir resistance 
mutations (p<0·001). Tenofovir resistance mutations at 
Lys65 or Lys70 were present in 92 (86%) of 107 patients 
with TAM mutations without Thr215Phe/Tyr, and 
one (13%) of eight patients with TAM mutations with 
Thr215Phe/Tyr (p<0·0001).
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Figure 2: Estimated prevalence of drug resistance mutations
Prevalence of resistance to nevirapine or efavirenz (NNRTIs), tenofovir, and cytosine analogue by presence or 
absence of TAM mutations. TAM=thymidine analogue mutation. Tenfovir=tenofovir disoproxil fumarate. 
NNRTI=non-nucleoside reverse transcriptase inhibitor. 
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We found a signiﬁ cant association between TAMs and 
tenofovir resistance both at the study-level and the 
individual-level. Studies with the highest prevalence of 
TAMs tended to also have the most tenofovir resistance 
(ﬁ gure 3A, Spearman’s ρ of study-level resistance 
was 0·64, p<0·0001). For example, in the ten studies in 
which less than 15% of patients had TAMs, tenofovir 
resistance was present in 112 (52%) of 216 patients, 
whereas in the ten studies with more than 15% of patients 
with TAMs, tenofovir resistance was present in 333 (67%) 
of 496 patients (p<0·0001). We found similar associations 
for other drug resistance mutations, such as higher levels 
of nevirapine or efavirenz resistance and cytosine 
analogue resistance in patients with TAMs (appendix). 
Within the study, patients with a TAM were more likely 
to also have tenofovir resistance (odds ratio 1·29, 
95% CI 1·16–1·43; ﬁ gure 3B). The association was 
maintained among patients stratiﬁ ed by co-administered 
cytosine analogue, co-administered nevirapine or 
efavirenz, sex, baseline viral load (<log105 copies per mL vs 
≥log105 copies per mL), or baseline CD4 count (<100 cells 
per μL vs ≥100 cells per μL; ﬁ gure 4). Notably, OR for 
tenofovir resistance was not aﬀ ected by the possibility of 
within study drug substitution of thymidine analogue for 
tenofovir (ﬁ gure 4). We found similar, although slightly 
weaker, within-study associations of TAM mutations with 
both nevirapine or efavirenz resistance and cytosine 
analogue resistance (appendix).
We assessed studies for potential within-programme 
drug substitutions and whether viral load conﬁ rmation 
was sought beforehand (table 2). We found that thymidine 
analogue substitution for tenofovir had occurred and that 
suppression was rarely conﬁ rmed before the change in 
treatment. Three studies implemented resistance testing 
before initiating tenofovir, although none excluded 
patients with drug resistance from initiating ﬁ rst line ART. 
Discussion
We found TAMs that are speciﬁ cally selected by 
zidovudine or stavudine in roughly 16% of patients 
with failure of tenofovir-based ﬁ rst-line antiretroviral 
regimens. TAMs were associated with greater drug 
resistance to all components of WHO recommended, 
tenofovir-containing ﬁ rst-line treatment. The prevalence 
of resistance to tenofovir reached 80% in individuals 
with TAMs, a result that is concerning and very much 
unexpected given that the tenofovir mutation Lys65Arg 
and TAMs are thought to be antagonistic to one another.17 
Patients with TAMs tended to have lower CD4 counts 
than did patients without TAMs, which is consistent with 
longer duration of infection or faster disease progression.
Our drug resistance prevalence estimates represent 
prevalence for participants with documented virological 
failure. Although it is important to know the prevalence 
of drug resistance among all participants treated with 
ﬁ rst-line therapy, this was not possible, mostly because of 
the absence of a clear denominator in many sites. A large 
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11
12
13
13
21
24
21
16
31
41
56
15
Odds ratio (95% CI)
2·67 (0·87–8·17)
1·17 (0·47–2·93)
2·03 (0·78–5·31)
1·38 (0·69–2·72)
1·07 (0·65–1·78)
1·34 (1·10–1·63)
1·10 (0·89–1·37)
1·53 (1·10–2·13)
No TAMs
No TDF resistance
1·29 (1·13–1·47)
0·92 (0·21–4·06)
1·50 (0·57–3·95)
1·54 (0·95–2·51)
1·22 (0·83–1·80)
No TAMs
1·32 (0·97–1·80)
1·17 (0·26–5·29)
1·29 (0·88–1·89)
1·54 (0·96–2·46)
1·17 (0·87–1·58)
TAMs
1·27 (1·03–1·58)
1·29 (1·16–1·43)
Weight (%)
 0·84
 2·36
 1·14
 3·08
 6·86
 15·78
 23·20
 12·10
 0·00
 0·00
 65·35
 1·54
 1·45
 3·81
 4·98
 0·00
 11·79
 1·25
 4·94
 4·65
 12·02
 0·00
 22·86
 100·00
10·1 0·2 0·5 2 5 10
Less resistance
with TAMs
More resistance
with TAMs
B
A
Eastern Africa
Southern Africa
Western or central Africa
Figure 3: Study-level prevalence of TAMs and association with tenofovir resistance
(A) Scatter plot of study-level prevalence of tenofovir resistance and prevalence of TAMs by region. Markers are 
weighted by study size. (B) Meta-analysis of odds ratios for tenofovir resistance in participants with TAMs versus 
those without TAMs within individual studies. TAM=thymidine analogue mutation. Tenfovir=tenofovir 
disoproxil fumarate.
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international meta-analysis11 reported that 15–35% of 
patients initiating ART in sub-Saharan Africa have 
virological failure by 12 months. In view of our prevalence 
estimate of 16% of patients with virological failure having 
TAMs, we estimate that between 2% and 6% of individuals 
treated with tenofovir plus cytosine analogue plus 
efavirenz will have TAMs and 2–5% would have drug 
resistance to thymidine analogues, tenofovir, cytosine 
analogues, and the NNRTIs nevirapine and efavirenz 
within 1 year of treat ment initiation under current 
practices in sub-Saharan Africa. As previously reported,15 
an additional 8–18% of patients are likely to have 
resistance to tenofovir, cytosine analogues, and NNRTIs, 
but without thymidine analogue resistance.
There are three possible sources of TAMs in patients 
on ﬁ rst-line tenofovir. The ﬁ rst is transmitted drug 
resistance, which is unlikely to account for the majority 
of cases in this study because transmitted drug resistance 
of TAMs is rare (<1% of TAMs in untreated patients 
result from being transmitted).18,19 Additionally, TAMs 
and Lys65Arg are antagonistic at the level of the viral 
genome;17 our ﬁ ndings showing co-existence of TAMs 
and Lys65Arg in patients with virological failure possibly 
result from these mutations occurring on diﬀ erent viral 
genomes after sequential therapies. Because trans-
mission is usually with a single viral variant, transmitted 
drug resistance with TAM would translate to a viral 
population within an individual that consists entirely of 
TAM-containing viruses (or reversion variants). Under 
this scenario antagonism with Lys65Arg would be active 
and we would therefore not expect to see Lys65Arg and 
TAMs together in the same individuals.
The second possibility is programmatic substitution, 
wherein tenofovir was used to replace a thymidine 
analogue at a time when the patient had occult treatment 
failure. Under this scenario the most likely sequence of 
events would be, ﬁ rst, acquisition of cytosine analogue 
resistance, TAM, and NNRTI mutations during 
prolonged viral failure, followed by a switch to tenofovir 
and subsequent emergence of Lys65Arg that confers 
tenofovir resistance. Therefore, prevention of the 
develop ment of Lys65Arg mutation could only be 
achieved by viral load suppression conﬁ rmation before 
the switch in treatments. Eﬀ ective viral load monitoring 
has been identiﬁ ed as a priority area20 and would trigger 
adherence counselling and then a possible switch to a 
second-line protease inhibitor-based regimen instead of 
continuation of a failing ﬁ rst-line regimen with the 
substitution of a thymidine analogue for tenofovir. 
A large study in Myanmar (where tenofovir substitution 
is planned) has monitored viral loads in more than 
4000 patients after 12 months of thymidine analogue-
based ART, with the aim of avoiding substitutions in 
viraemic patients. The investigators found that 
13% of patients had viral loads greater than 250 copies 
per mL, which was halved after adherence counselling 
was done, reinforcing the need for viral load monitoring 
before drug substitution.21
However, the second scenario cannot account for 
many of the TAMs identiﬁ ed in the present study 
because we detected TAMs in cohorts in which no 
programmatic substitution had occurred and tenofovir-
based ART was used at the outset in apparently 
untreated patients (table 2).22,23 The third possibility, 
which we believe could account for most of the TAMs in 
the present study is previous undisclosed ART use with 
undocumented viral failure and drug resistance. This 
hypothesis is supported by the lower CD4 counts 
detected in patients with TAMs. Moreover, signiﬁ cant 
variation has been reported in viral load monitoring 
practices between rural and urban settings in South 
Africa,24 possibly explaining how unrecognised viral 
failure and drug resistance during tenofovir substitution 
could occur in settings where viral load monitoring is 
centrally funded and part of national guidelines.
To prevent drug resistance due to undisclosed previous 
ART use, accessible point-of-care baseline resistance 
screening25 could be used to assist in the identiﬁ cation of 
patients with resistance to the components of ﬁ rst-line 
Sex
Male
Female
Co-administered cytosine analogues
Lamivudine
Emtricitabine
Co-administered NNRTI
Efavirenz
Nevirapine
Baseline CD4 count (cells per μL)
<100
≥100
Unavailable
Baseline log10 viral load (copies HIV-1 RNA per mL)
<5 
≥5
Missing data
Substitution of thymidine analogue for tenofovir within study
Yes
Possibly
No
241
369
152
496
230
395
201
169
234
58
99
464
267
154
232
1·17 (0·98–1·41)
1·31 (1·14–1·50)
1·39 (1·10–1·75)
1·25 (1·11–1·40)
1·22 (1·02–1·44)
1·35 (1·17–1·56)
1·19 (1·03–1·38)
1·31 (0·97–1·77)
1·27 (1·05–1·53)
1·57 (1·07–2·29)
1·21 (0·84–1·74)
1·23 (1·09–1·39)
1·23 (1·07–1·41)
1·54 (1·13–2·10)
1·27 (1·05–1·54)
Odds ratio (95% CI)
10·3 0·5 2 3
Number of
patients
Less resistance with TAMs More resistance with TAMs
Figure 4: Eﬀ ect of TAMs on tenofovir resistance in subgroups of patients
Within-study odds ratios for tenofovir resistance by presence or absence of TAMs, stratiﬁ ed by baseline 
characteristics. TAM=thymidine analogue mutation. Tenfovir=tenofovir disoproxil fumarate. NRTI=nucleoside 
reverse transcriptase inhibitor. NNRTI=non-nucleoside reverse transcriptase inhibitor. 
Articles
www.thelancet.com/infection   Published online November 30, 2016   http://dx.doi.org/10.1016/S1473-3099(16)30469-8 7
ART. We have previously identiﬁ ed key mutations that 
could be used in such assays, including Lys65Arg, 
Lys103Asn, Val106Met, Tyr181Cys, Gly190Ala, and 
Met184Val,26 and on the basis of the present study, 
Asp67Asn and Lys219Gln/Glu could be added to this list. 
If HIV-1 drug resistance is detected with such assays, 
second-line ART could be initiated, taking into account 
the mutations identiﬁ ed. If they become suﬃ  ciently cheap 
and reliable, drug resistance assays could be used in place 
of viral load monitoring at treatment initiation or switches.
Our study has some limitations. The sampling was not 
systematic and therefore prevalence estimates might not 
be fully representative of countries and regions. Our 
drug resistance prevalence estimates represent 
prevalence for participants with documented virological 
failure. We can only estimate the overall number 
initiating treatment, because it was not systematically 
assessed. Using data from WHO and Uganda on the 
prevalence of virological failure,11,23 we calculate that if 
15% of people initiating ART have failure at 1 year (on 
treatment analysis), then our data represent about 
4750 patients initiating tenofovir-based ﬁ rst-line ART.
Although none of the studies overtly used targeted 
viral load testing in individuals suspected of having 
treatment failure, such targeting might have occurred at 
the clinical level, potentially biasing our estimates 
of TAM resistance upwards. Conversely, Sanger 
sequencing can miss drug resistance mutations in 30% 
or more of patients.27 Additionally, we did not assess 
thymidine analogue resistance conferred by mutations 
in the connection domain between HIV-1 reverse 
transcriptase and RNAseH that are known to be selected 
by zidovudine,28 leading to further underestimation of 
drug resistance.
Notably, stavudine selects not only for TAMs, but also 
for Lys65Arg in up to 20% of patients who have failure of 
stavudine.9,29–31 However, given that TAM and Lys65Arg 
are not selected together by a single stavudine-based 
regimen,9,29,32 exposure to stavudine would probably not 
explain the genotypes with both TAM and Lys65Arg that 
were seen in our study.
This study has important policy implications for the 
limitation of drug resistance as tenofovir becomes more 
widely used both as treatment8 and pre-exposure 
prophylaxis.33 First, a single point-of-care viral load test 
could be implemented to prevent substitution of ﬁ rst 
line zidovudine for tenofovir in patients with virological 
failure. Regular viral load monitoring has been advocated 
in the past for treatment monitoring and could identify 
early virological failure in patients with previously 
undisclosed ART and drug resistance. However, this 
regular monitoring might be less cost eﬀ ective than 
Substitution of 
thymidine analogue for 
tenofovir within study?
Virus suppression 
always conﬁ rmed 
before substitution?
Baseline 
resistance testing?
Exclusion of 
patients with 
baseline resistance?
Possibility of 
previous 
undisclosed ART
Eastern Africa
PASER Uganda Possibly No No NA Yes
CDC Kenya ADR No No No NA Yes
TDF AMPATH, Kenya No No No NA Yes
UVRI/MoH Uganda surveillance study No NA Yes No Yes
CDC/MoH, Tanzania Possibly No No No Yes
West and central Africa
ACTION, Nigeria Yes No No NA Yes
ACTION Plus UP, Nigeria Possibly No No No Yes
Harvard/APIN PEPFAR Yes No No NA Yes
Doris Duke Study, Nigeria Yes No No NA Yes
Lubumbashi, DR Congo No NA Yes No Yes
Southern Africa
PASER Zambia Possibly Not always No NA Yes
PASER South Africa Possibly Not always No NA Yes
Africa Centre, South Africa Yes Not always No NA Yes
Aurum, South Africa Yes Not always No NA Yes
Bloemfontein, South Africa Yes Not always No NA Yes
KZN, South Africa Yes Not always No NA Yes
MSF Swaziland Yes No No NA Yes
OCTANE South Africa No NA Yes No Yes
CDC Zambia ADR No No No NA Yes
RFVF Durban, South Africa Possibly No No No Yes
ART=antiretroviral therapy. NA=not applicable. Tenfovir=tenofovir disoproxil fumarate.
Table 2: Study-level information on implementation of tenofovir-based ART 
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targeted viral load measurement. Second, simple 
resistance test kits could both assist in screening for 
drug resistance before ART initiation and also contribute 
to population level surveillance of HIV-1 drug resistance25 
in both treated and untreated populations—a priority in 
sub Saharan Africa given the substantial mortality now 
recognised to be associated with HIV-1 drug resistance.5 
These proposals should be part of a multipronged 
approach and subjected to cost eﬀ ectiveness assessment 
in the wider context of other interventions that aim to 
limit burden of the HIV epidemic.
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